Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 67.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,935 shares of the company’s stock after selling 35,520 shares during the quarter. SG Americas Securities LLC’s holdings in Amneal Pharmaceuticals were worth $103,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Amneal Pharmaceuticals by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock valued at $57,174,000 after purchasing an additional 412,599 shares in the last quarter. BlackRock Inc. lifted its stake in Amneal Pharmaceuticals by 10.8% in the 2nd quarter. BlackRock Inc. now owns 8,007,996 shares of the company’s stock valued at $24,825,000 after buying an additional 778,523 shares in the last quarter. Millennium Management LLC boosted its holdings in Amneal Pharmaceuticals by 153.3% in the 4th quarter. Millennium Management LLC now owns 5,013,378 shares of the company’s stock worth $9,977,000 after buying an additional 3,034,426 shares during the last quarter. Morgan Stanley increased its stake in Amneal Pharmaceuticals by 935.8% during the 4th quarter. Morgan Stanley now owns 4,220,998 shares of the company’s stock worth $8,400,000 after buying an additional 3,813,489 shares in the last quarter. Finally, Rubric Capital Management LP raised its holdings in shares of Amneal Pharmaceuticals by 54.7% during the third quarter. Rubric Capital Management LP now owns 4,024,500 shares of the company’s stock valued at $16,983,000 after acquiring an additional 1,423,121 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMRX. The Goldman Sachs Group lifted their price target on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research note on Monday, March 4th. Barclays raised their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $7.31.

Amneal Pharmaceuticals Trading Up 1.1 %

Shares of AMRX opened at $5.42 on Friday. The company has a current ratio of 1.63, a quick ratio of 0.94 and a debt-to-equity ratio of 121.31. The firm has a market capitalization of $1.66 billion, a P/E ratio of -17.48 and a beta of 1.33. The firm has a 50-day moving average price of $5.72 and a 200 day moving average price of $5.14. Amneal Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $6.46.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.5 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.